Consequences of Contracting COVID-19 or Taking the COVID-19 Vaccine for Individuals with a History of Lyme Disease

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2023 Mar 29

PMID 36978360

Authors

Daniel J Cameron

Sean R McWhinney

Affiliations

Soon will be listed here.

Abstract

Individuals with Lyme disease can be very symptomatic. This survey compares the burden of illness for individuals with a history of Lyme disease (HLD) with individuals with a HLD who have either contracted COVID-19 or who have taken the COVID-19 vaccine. The findings describe the relative symptom burden among these three groups using a cross-sectional descriptive survey investigating the burden of Lyme disease in a pandemic. The survey includes the General Symptom Questionnaire-30 (GSQ-30), a brief self-report scale designed to assess the symptom burden in Lyme disease (LD). The results of this survey show that the overall burden of illness among individuals with HLD is not significantly different after contracting COVID-19 or after COVID-19 vaccination. A new survey will be needed to better understand why one in five individuals with a HLD reported long COVID after contracting COVID-19. These results should help clinicians and their patients to discuss the consequences of contracting a COVID-19 infection or being vaccinated against COVID-19.

Citing Articles

Combining Double-Dose and High-Dose Pulsed Dapsone Combination Therapy for Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome and Co-Infections, Including Bartonella: A Report of 3 Cases and a Literature Review.

Horowitz R, Fallon J, Freeman P Microorganisms. 2024; 12(5).

PMID: 38792737 PMC: 11124288. DOI: 10.3390/microorganisms12050909.

Comparison of the Efficacy of Longer versus Shorter Pulsed High Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome with Bartonellosis and Associated Coinfections.

Horowitz R, Fallon J, Freeman P Microorganisms. 2023; 11(9).

PMID: 37764145 PMC: 10537894. DOI: 10.3390/microorganisms11092301.

References

Logigian E, Kaplan R, Steere A . Chronic neurologic manifestations of Lyme disease. N Engl J Med. 1990; 323(21):1438-44. DOI: 10.1056/NEJM199011223232102. View

Halperin J, Little B, Coyle P, Dattwyler R . Lyme disease: cause of a treatable peripheral neuropathy. Neurology. 1987; 37(11):1700-6. DOI: 10.1212/wnl.37.11.1700. View

McAuliffe P, Brassard M, Fallon B . Memory and executive functions in adolescents with posttreatment Lyme disease. Appl Neuropsychol. 2008; 15(3):208-19. DOI: 10.1080/09084280802324473. View

Aiyegbusi O, Hughes S, Turner G, Cruz Rivera S, McMullan C, Chandan J . Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021; 114(9):428-442. PMC: 8450986. DOI: 10.1177/01410768211032850. View

Aucott J, Soloski M, Rebman A, Crowder L, Lahey L, Wagner C . CCL19 as a Chemokine Risk Factor for Posttreatment Lyme Disease Syndrome: a Prospective Clinical Cohort Study. Clin Vaccine Immunol. 2016; 23(9):757-66. PMC: 5014924. DOI: 10.1128/CVI.00071-16. View

Maksimyan S, Syed M, Soti V . Post-Treatment Lyme Disease Syndrome: Need for Diagnosis and Treatment. Cureus. 2021; 13(10):e18703. PMC: 8507427. DOI: 10.7759/cureus.18703. View

Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale K . Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022; 28(8):1706-1714. PMC: 9388369. DOI: 10.1038/s41591-022-01909-w. View

Fallon B, Keilp J, Corbera K, Petkova E, Britton C, Dwyer E . A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology. 2007; 70(13):992-1003. DOI: 10.1212/01.WNL.0000284604.61160.2d. View

Sigra S, Hesselmark E, Bejerot S . Treatment of PANDAS and PANS: a systematic review. Neurosci Biobehav Rev. 2018; 86:51-65. DOI: 10.1016/j.neubiorev.2018.01.001. View

10.

Krupp L, Hyman L, Grimson R, Coyle P, Melville P, Ahnn S . Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology. 2003; 60(12):1923-30. DOI: 10.1212/01.wnl.0000071227.23769.9e. View

11.

Fallon B, Nields J . Lyme disease: a neuropsychiatric illness. Am J Psychiatry. 1994; 151(11):1571-83. DOI: 10.1176/ajp.151.11.1571. View

12.

Sanchez-Ramirez D, Normand K, Zhaoyun Y, Torres-Castro R . Long-Term Impact of COVID-19: A Systematic Review of the Literature and Meta-Analysis. Biomedicines. 2021; 9(8). PMC: 8389585. DOI: 10.3390/biomedicines9080900. View

13.

Logigian E, Kaplan R, Steere A . Successful treatment of Lyme encephalopathy with intravenous ceftriaxone. J Infect Dis. 1999; 180(2):377-83. DOI: 10.1086/314860. View

14.

Kanjwal K, Karabin B, Kanjwal Y, Grubb B . Postural orthostatic tachycardia syndrome following Lyme disease. Cardiol J. 2011; 18(1):63-6. View

15.

Singh A, Khillan R, Mishra Y, Khurana S . The safety profile of COVID-19 vaccinations in the United States. Am J Infect Control. 2021; 50(1):15-19. PMC: 8539830. DOI: 10.1016/j.ajic.2021.10.015. View

16.

Fallon B, Zubcevik N, Bennett C, Doshi S, Rebman A, Kishon R . The General Symptom Questionnaire-30 (GSQ-30): A Brief Measure of Multi-System Symptom Burden in Lyme Disease. Front Med (Lausanne). 2019; 6:283. PMC: 6908481. DOI: 10.3389/fmed.2019.00283. View

17.

Klempner M, Hu L, Evans J, Schmid C, JOHNSON G, Trevino R . Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001; 345(2):85-92. DOI: 10.1056/NEJM200107123450202. View

18.

Muehlenbachs A, Bollweg B, Schulz T, Forrester J, Carnes M, Molins C . Cardiac Tropism of Borrelia burgdorferi: An Autopsy Study of Sudden Cardiac Death Associated with Lyme Carditis. Am J Pathol. 2016; 186(5):1195-205. DOI: 10.1016/j.ajpath.2015.12.027. View

19.

Crook H, Raza S, Nowell J, Young M, Edison P . Long covid-mechanisms, risk factors, and management. BMJ. 2021; 374:n1648. DOI: 10.1136/bmj.n1648. View